Newsletter | March 22, 2023

03.22.23 -- A Bridge To Capacity For Cell & Gene Industry
 
Sponsor
From The Editor
A Bridge To Capacity For The Cell And Gene Industry
 
By Louis Garguilo, chief editor, Outsourced Pharma

Bridge facilities have been built for cell and gene therapy (CGT) sponsors — and CDMOs — to access here-and-now available, fully outfitted GxP capacity. But bring your own skilled workers. Here's how it works.
Featured Editorial
Strategic Procurement For Emerging Pharmas And Biotechs
 
By Dave Stowe, Bill Connell, and Ben Sahacic

Emerging pharma and biotech companies depend significantly on suppliers, from initial discovery to clinical trials and regulatory approval. As a result, the sourcing and procurement function requires a strategic mindset aligned with business goals to drive an efficient purchasing process throughout the entire supply chain.
Industry Insights
Top Four Considerations For Tech Transfer Performance
Article | By Lei Zheng, Biomedical Engineering, Pfizer CentreOne

Successful tech transfer is how long-term strategic CDMO relationships begin. A product’s continued success may hinge on this critical exchange of product data and required regulatory filings.
In-House Plasmid Production To Secure Supply Chains
Article | By Kristin Heller, Andrew Moreo, and Jonathan Rush, Andelyn Biosciences

A CDMO with in-house plasmid manufacturing capabilities can help companies accelerate timelines and ensure material availability, ultimately saving time and money throughout their product life cycle.
Challenges And Solutions In Cell And Gene Therapy Manufacturing
White Paper | By Yatindra Tirunagari and Kassim Kolia, Rentschler Biopharma

Discover the three major challenges cell and gene therapy manufacturers are facing today and experienced insights on how to overcome them.
A Plasmid DNA Purification Process For Viral Vector, mRNA, Vaccine Therapies
e-book | MilliporeSigma

Guidance for your plasmid DNA downstream process development, exploring cell harvest, lysis, neutralization and clarification, chromatographic purification, TFF, and sterile filtration unit operations.
The Future Of Plug-And-Play Large-Scale Viral Vector Manufacturing
Poster | AGC Biologics

Explore AAV-based gene therapy production to manage adherent and suspension processes, and new approaches for creating large-scale AAV production that can meet any product specification.
Sponsor
Solutions
Analytical Services: Capabilities And Expertise
Cambrex
Outsourced Pharma Live
 

Available On Demand! Throughout the year, chief editor Louis Garguilo brings together industry experts to discuss some of the biggest challenges being faced by both sponsors and CDMOs. Our archived videos can be accessed at any time by registered site users.